It is noteworthy to mention that coronavirus disease (COVID-19) reportedly increases mortality rates for OHCAs, as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) interacts closely with angiotensin-converting enzyme-2 (ACE2) receptors on myocardial cells that could mediate SARS-CoV-2 into myocardial cells and cause cardiotoxicity [8, 9]. This evidence concerns the gene ACE2 and COVID-19.